XETR
SBX
Market cap6mUSD
Jul 09, Last price
1.16EUR
1D
0.00%
1Q
-39.90%
Name
SynBiotic SE
Chart & Performance
P/E
—
P/S
1.43
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.91%
Rev. gr., 5y
%
Revenues
4m
-52.71%
Net income
-11m
L-56.36%
CFO
-3m
L-58.20%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SynBiotic SE is dedicated to pioneering cannabinoid-based pharmaceuticals and readily available health and wellness items. Its primary strategic pillars include the laboratory synthesis of cannabinoids, advanced drug discovery, the formulation of dietary aids, and the creation of cosmetic solutions. Formerly operating as Ledgertech SE, the company is headquartered in Munich, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||